Journal News

Calcium channel linked to cancer drug resistance

Emily Ulrich
June 12, 2025

Chemotherapy tumor resistance develops after long-term regimens of the platinum-containing anticancer drug carboplatin. Scientists have observed an enlarged cell morphology and involvement of T-type calcium channels in resistant ovarian cancer cells. Sooyun Kim and researchers at Seoul National University wanted to find out if these characteristics also relate to carboplatin resistance seen in retinoblastoma, an aggressive childhood cancer. They published their findings in a recent Journal of Biological Chemistry article.

Large-scale mosaic confocal microscopy image of a mouse retina
Kenyoung Kim, Wonkyu Ju and Mark Ellisman, National Center for Microscopy and Imaging Research, University of California, San Diego
Large-scale mosaic confocal microscopy image of a mouse retina.
The authors generated a resistant population of retinoblastoma cells in the lab by exposing a retinoblastoma cell line to carboplatin. They observed a larger proportion of giant cells in the resistant subset compared to the original cell line. They also measured whole-cell electrical current of the resistant cells and determined that the giant cells had more sustained calcium currents compared to regularly sized resistant cells.

Immunofluorescence staining and pharmacological inhibition experiments identified the Cav3.3 channel as the overexpressed calcium channel subtype that contributes to the sustained currents. The authors further showed that messenger RNA expression levels only for Cav3.3 increased after carboplatin exposure, while the levels for the other Cav3.1 and Cav3.2 subtypes slightly decreased in the resistant cells relative to the original retinoblastoma strain.

Finally, the researchers determined that treating the resistant retinoblastoma giant cells with a Cav3.3 inhibitor increased their sensitivity to carboplatin. They only observed this increase in carboplatin sensitivity in the resistant cells and not in the original retinoblastoma strain, indicating that Cav3.3 plays a specific role in drug resistance.

Cav3.3 could potentially be a target for the treatment of carboplatin-resistant retinoblastoma. Future experiments will help identify additional proteins and pathways that may connect Cav3.3 to chemotherapeutic resistance in retinoblastoma and whether the involvement of Cav3.3 over the other channel subtypes is observed in other cancers.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
News

Cracking cancer’s code through functional connections

July 2, 2025

A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.